Table 2.

Association of Statin Use With All-Cause Mortality, Major Cardiovascular Events, and Hospitalizations in 7,970 U.S. Veterans With HFpEF and Free of ASCVD at Baseline, After Propensity Score Overlap Weighting

	Statin User N = 3,759	Statin Nonuser N = 7,970	Outcome	HR (95% CI)	P Value
Primary outcome	# events/1,000 person-y	# events/1,000 person-y	Weighted incidence rate difference/1,000 person-y (95% CI)
All-cause mortality	2,031/22.5	3,283/25.2	−23.55 (−29.87, −17.23)	0.78 (0.73-0.83)	<0.001
MACE compositea	1,576/13.9	3,283/18.8	−46.33 (−56.38, −36.29)	0.79 (0.74-0.84)	<0.001
Secondary outcome	# days hospitalized/1,000 person-y	# days hospitalized/1,000 person-y	Risk difference (difference in # days hospitalized/y)
All-cause hospitalization days per y	108.0/22.3	169.2/24.8	−2.11 (−2.97, −1.26)	0.69 (0.60-0.80)	<0.001
HF-specific hospitalization days per y	41.4/22.3	61.3/24.8	−0.69 (−1.12, −0.26)	0.72 (0.59-0.88)	<0.001

ASCVD = atherosclerotic cardiovascular disease; HF = heart failure; HFpEF = heart failure with preserved ejection fraction; MACE composite = major adverse cardiovascular events composite.

^aMACE composite = MI/MI death, stroke/stroke death, revascularization.